<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082236</url>
  </required_header>
  <id_info>
    <org_study_id>SAP101</org_study_id>
    <nct_id>NCT02082236</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcelRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcelRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the single and multiple-dose pharmacokinetics (PK)
      of sublingual administration of the Sufentanil Sublingual Microtablet (SSM) 30 mcg and
      compare the pharmacokinetics of a single dose of SSM 30 mcg to 2 doses of SSM 15 mcg
      administered 20 minutes apart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>9 days, not including a 30 day screening window</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time curve</description>
  </primary_outcome>
  <other_outcome>
    <measure>C max</measure>
    <time_frame>9 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>T max</measure>
    <time_frame>9 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to reach maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Context Sensitive Half-Time  (CST½)</measure>
    <time_frame>9 hours</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A:  Sufenta® IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B:  SSM 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SSM 30 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C:  2 consecutive doses of SSM 15 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 consecutive doses of SSM 15 mcg administered 20 minute apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D:  SSM 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 consecutive doses of SSM 30 mcg administered 1 hour apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Arm A: Sufenta</intervention_name>
    <arm_group_label>Treatment A:  Sufenta® IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B:  Sufentanil SSM 30 mcg</intervention_name>
    <arm_group_label>Treatment B:  SSM 30 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: 2 consecutive doses of SSM 15 mcg administered 20 minutes apart</intervention_name>
    <arm_group_label>Treatment C:  2 consecutive doses of SSM 15 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D: SSM 30 mcg</intervention_name>
    <description>12 consecutive doses of SSM 30 mcg administered 1 hour apart</description>
    <arm_group_label>Treatment D:  SSM 30 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-smoking male or female subjects

          2. Aged between 18 and 45 years inclusive

          3. Subjects must have Body Mass Index (BMI) between 18 and 30, inclusively.

        Exclusion Criteria:

          1. Subjects who are taking over-the-counter medication (except for single dose
             multi-vitamin supplements or acetaminophen of less than 2 g/day) within 14 days prior
             to start of sufentanil dosing prescription medications or over the counter (OTC)
             medications

          2. Female subjects who are pregnant

          3. Subjects with chronic obstructive pulmonary disease, sleep apnea, or other
             significant respiratory disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra K. Willsie, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasma concentrations</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
